<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23183" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperkalemic Periodic Paralysis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sekhon</surname>
            <given-names>Dilraj S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaqar</surname>
            <given-names>Sarosh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dilraj Sekhon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarosh Vaqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23183.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperkalemic periodic paralysis is a rare condition presenting as temporary periods of severe muscle weakness or paralysis. To treat this condition appropriately, clinicians need to diagnose this condition in a timely fashion and provide the patient with the appropriate care and referrals. This activity reviews the evaluation and treatment of hyperkalemic periodic paralysis and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the presentation of a patient with hyperkalemic periodic paralysis.</p></list-item><list-item><p>Explain the pathophysiology of hyperkalemic periodic paralysis.</p></list-item><list-item><p>Outline the management considerations for patients with hyperkalemic periodic paralysis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23183">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23183.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Periodic paralysis is a group of inherited diseases that present as episodic muscle weakness and paralysis. Hyperkalemic periodic paralysis (HYPP,&#x000a0;HyperKPP) is a rare condition that begins in childhood and can continue until middle adulthood or may even last into late adulthood. It presents as muscle weakness, ranging from mild weakness to paralysis. During these episodes, it is common to have higher than normal blood levels of potassium.<xref ref-type="bibr" rid="article-23183.r1">[1]</xref>&#x000a0;[Level 5]</p>
        <p>The condition is caused by a mutation in the SCN4A gene that codes for voltage-gated sodium channel Na1.4. Several diagnostic modalities exist in assisting diagnosis, such as genetic testing, although they are not always definitive. Treatment for HYPP is both proactive and reactive, with avoidance of triggers being the mainstay of therapy. It is important to diagnose this condition quickly and accurately as long-term complications, including weakness and fatigue, can lead to a decrease in the quality of life.</p>
      </sec>
      <sec id="article-23183.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hyperkalemic periodic paralysis is caused by a point mutation in the SCN4A gene.<xref ref-type="bibr" rid="article-23183.r2">[2]</xref>&#x000a0;[Level 5]&#x000a0;This gene encodes proteins responsible for sodium transport in skeletal muscles.<xref ref-type="bibr" rid="article-23183.r3">[3]</xref>&#x000a0;[Level 4]</p>
      </sec>
      <sec id="article-23183.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There is an estimated prevalence of 1 to 200,000 cases, affecting women and men equally, making this condition quite rare.<xref ref-type="bibr" rid="article-23183.r4">[4]</xref></p>
      </sec>
      <sec id="article-23183.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The SCN4A protein is responsible for the control of sodium influx into skeletal muscles that aid in contraction. Mutant SCN4A&#x000a0;protein channels malfunction by allowing too much sodium into skeletal muscles by staying open too long or not staying closed long enough. This additional influx of sodium triggers a release of intracellular potassium from the skeletal muscles. Subsequently, this change in ion transport impairs a muscle's ability to contract, leading to weakness or paralysis.<xref ref-type="bibr" rid="article-23183.r3">[3]</xref></p>
      </sec>
      <sec id="article-23183.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients typically present in the first or second decade of life with intermittent bouts of weakness or paralysis in the hips, shoulders, and back triggered by diet, stress, or exercise. Attacks are generally intermittent and last 15 minutes to 1 hour. Affected individuals may also present with paramyotonia (muscle stiffness or inability to relax muscles). Approximately 50% of affected individuals will present with weakness or paralysis before age 10. The attacks initially are uncommon; however, they increase in intensity and frequency until the fifth decade of life, at which point there is a steep decline. Common triggers are potassium-rich foods, a cold environment, and rest after physical activity. Attacks may last from 15 minutes to 1 hour. Individuals over 40 years of age commonly report permanent muscle weakness, with a third of individuals developing chronic progressive myopathy.<xref ref-type="bibr" rid="article-23183.r5">[5]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23183.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis is initially guided by the clinical presentation of the affected individual. This includes intermittent paralysis and/or paramyotonia after certain triggers. Diagnosis is based primarily on several criteria, which include a history of transient episodes of weakness, ictal serum potassium levels, electromyography, and exclusion of secondary causes. The proposed diagnostic criteria are as follows: 2 or more attacks of weakness with serum potassium greater than 4.5 mEq/L&#x000a0;or 1 attack in the patient with a relative with 1 attack with serum potassium greater than 4.5 mEq/L.&#x000a0;</p>
        <p>In addition, 3 of the 6 following clinical or laboratory features can also assist in making a diagnosis: symptom onset before age 30; attacks must last less than 2 hours; identifiable triggers, myotonia; family history; confirmed genetic testing for sodium channel mutation in the SCN4A, or positive McManis short exercise test.<xref ref-type="bibr" rid="article-23183.r6">[6]</xref>[Level 4] Additionally, other causes must be excluded.<xref ref-type="bibr" rid="article-23183.r5">[5]</xref></p>
        <p>Historically, provocative tests&#x000a0;were&#x000a0;utilized to establish a diagnosis. However, due to the risk of inducing severe attacks, they are no longer recommended.&#x000a0;Muscle biopsy is not recommended due to the lack of specific findings as well as the lack of influence on management.<xref ref-type="bibr" rid="article-23183.r7">[7]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23183.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment approach should include both the management of acute attacks and the prevention of attacks. Treatments include behavioral interventions directed at avoiding triggers and modifying potassium levels through diet, diuretics, and carbonic anhydrase inhibitors. Attacks may be&#x000a0;treated&#x000a0;at the onset of weakness with mild physical activity, oral intake of carbohydrate-rich foods, salbutamol inhalation, or intravenous calcium gluconate.<xref ref-type="bibr" rid="article-23183.r8">[8]</xref>&#x000a0;[Level 3]</p>
        <p>Individuals may&#x000a0;prevent&#x000a0;attacks by consuming frequent carbohydrate-rich meals, a thiazide diuretic, or a carbonic anhydrase inhibitor. Individuals should avoid&#x000a0;potassium-rich medications and foods, fasting, strenuous work, and exposure to cold to prevent attacks. Surveillance methods include scheduled evaluation of neurologic status. Individuals who develop permanent muscle weakness may require lifelong thiazide diuretics and interval MRI of the proximal leg muscle every 1 to 3 years.</p>
        <p>Prophylactic treatment necessitates serum potassium levels twice yearly to avoid diuretic complications and annual evaluation of thyroid function. It is imperative to avoid factors that may precipitate an episode. These include ingesting potassium-rich food or medications, prolonged fasting, intense physical activity, a cold environment, and depolarizing anesthetic agents that may be used during general anesthesia.<xref ref-type="bibr" rid="article-23183.r5">[5]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23183.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>As hyperkalemic periodic paralysis presents in childhood, adult-onset of clinically similar symptoms suggest other etiology, either as Andersen-Tawil syndrome or other acquired hyperkalemic periodic paralysis.<xref ref-type="bibr" rid="article-23183.r9">[9]</xref>&#x000a0;[Level 5]&#x000a0;Common hereditary disorders that cause hyperkalemia include adrenal insufficiency, recessive infantile hypoaldosteronism, pseudohypoaldosteronism type 1, and pseudohypoaldosteronism type 2. Additionally, any individual may have periodic paralysis secondary to acquired sustained hyperkalemia.<xref ref-type="bibr" rid="article-23183.r10">[10]</xref><xref ref-type="bibr" rid="article-23183.r11">[11]</xref>&#x000a0;Moreover, a case of hyperkalemic periodic paralysis associated with multiple sleep-onset REM periods with concomitant daytime sleepiness has been reported in the literature, although a genetic analysis was not conducted.<xref ref-type="bibr" rid="article-23183.r12">[12]</xref>&#x000a0;[Level 4]</p>
      </sec>
      <sec id="article-23183.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The possible long-term sequelae confer a poor prognosis for those affected with this condition.&#x000a0;Although the episodic frequency classically decreases with age, the literature suggests that only 21% of those affected report this improvement.&#x000a0;Of affected individuals, 68% have reported permanent weakness, 82% have reported muscle pain, and up to 89% have reported fatigue.<xref ref-type="bibr" rid="article-23183.r13">[13]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23183.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Long-term complications from hyperkalemic periodic paralysis can range from minimal to severe lifelong symptoms that can decrease quality of life. They can include pain, fatigue, stiffness, weakness, injuries, and depression.<xref ref-type="bibr" rid="article-23183.r13">[13]</xref>&#x000a0;[Level 5]&#x000a0;</p>
        <p>Secondary complications are of concern for general anesthesia as commonly used drugs can cause&#x000a0;depolarizing effects on the musculature, which can worsen myotonic reactions, inducing spasms and stiffness. This can have detrimental effects on respiratory muscles. Glucose infusion, maintenance of normal body temperature, and low serum potassium should be maintained to prevent these complications.<xref ref-type="bibr" rid="article-23183.r14">[14]</xref><xref ref-type="bibr" rid="article-23183.r15">[15]</xref></p>
      </sec>
      <sec id="article-23183.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with a neurologist who is familiar with the diagnosis and management of hyperkalemic periodic paralysis is advised.</p>
      </sec>
      <sec id="article-23183.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Appropriate evaluation and genetic counseling remain the cornerstone of&#x000a0;patient education&#x000a0;for&#x000a0;individuals with hyperkalemic periodic paralysis and their families. It is relevant to evaluate asymptomatic relatives of affected individuals, allowing the appropriate preventative measures to be taken prior to adverse events.<xref ref-type="bibr" rid="article-23183.r5">[5]</xref>&#x000a0;[Level 3]</p>
      </sec>
      <sec id="article-23183.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interdisciplinary team can improve the quality of care and patient outcomes by coordinating efforts to provide comprehensive care. Firstly, primary care physicians must be familiar with the disease presentation and pathogenesis of hyperkalemic periodic paralysis. Once the correct diagnosis has been made, providing the correct treatment and preventative measures is important. It is important to make the patient aware of the different triggers of the condition. A referral to a knowledgeable registered dietician is necessary as preventative measures entail consuming and avoiding certain foods.</p>
        <p>A consultation with a geneticist is also necessary to evaluate the risk for future generations or asymptomatic relatives of the affected individual. Lastly, physical activity plays an integral role in the&#x000a0;long-term&#x000a0;management of potential complications, which may necessitate&#x000a0;a visit to a physical therapist. As evident, it is imperative to have an interdisciplinary approach with shared decision-making and open communication for optimal treatment of this condition.</p>
      </sec>
      <sec id="article-23183.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23183">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/hyperkalemic-periodic-paralysis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23183">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23183/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23183">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23183.s16">
        <title>References</title>
        <ref id="article-23183.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sansone</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Shieh</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Tawil</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Griggs</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Review of the Diagnosis and Treatment of Periodic Paralysis.</article-title>
            <source>Muscle Nerve</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>522</fpage>
            <page-range>522-530</page-range>
            <pub-id pub-id-type="pmid">29125635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Sodium Channelopathies of Skeletal Muscle.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2018</year>
            <volume>246</volume>
            <fpage>309</fpage>
            <page-range>309-330</page-range>
            <pub-id pub-id-type="pmid">28939973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lehmann-Horn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jurkat-Rott</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals.</article-title>
            <source>J Neurol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>260</volume>
            <issue>10</issue>
            <fpage>2606</fpage>
            <page-range>2606-13</page-range>
            <pub-id pub-id-type="pmid">23884711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurkat-Rott</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lehmann-Horn</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis.</article-title>
            <source>Neurotherapeutics</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-24</page-range>
            <pub-id pub-id-type="pmid">17395131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Weber</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperkalemic Periodic Paralysis</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>7</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">20301669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sansone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Links</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Panzeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Treatment for periodic paralysis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2008</year>
            <month>Jan</month>
            <day>23</day>
            <issue>1</issue>
            <fpage>CD005045</fpage>
            <pub-id pub-id-type="pmid">18254068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finsterer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Primary periodic paralyses.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-58</page-range>
            <pub-id pub-id-type="pmid">18031562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clausen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Clausen</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Na+,K+-pump stimulation improves contractility in isolated muscles of mice with hyperkalemic periodic paralysis.</article-title>
            <source>J Gen Physiol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>138</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-30</page-range>
            <pub-id pub-id-type="pmid">21708955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plaster</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Tawil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tristani-Firouzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Can&#x000fa;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bendahhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsunoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Iannaccone</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deymeer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nitu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozdemir</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serdaroglu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Subramony</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Pt&#x000e1;cek</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome.</article-title>
            <source>Cell</source>
            <year>2001</year>
            <month>May</month>
            <day>18</day>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>511</fpage>
            <page-range>511-9</page-range>
            <pub-id pub-id-type="pmid">11371347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Picco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garibaldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cotellessa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DiRocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borrone</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Corticosterone methyl oxidase type II deficiency: a cause of failure to thrive and recurrent dehydration in early infancy.</article-title>
            <source>Eur J Pediatr</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>151</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-3</page-range>
            <pub-id pub-id-type="pmid">1601005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Siguero</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Simic-Schleicher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sippell</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>2056</fpage>
            <page-range>2056-9</page-range>
            <pub-id pub-id-type="pmid">11344206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iranzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santamaria</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemic periodic paralysis associated with multiple sleep onset REM periods.</article-title>
            <source>Sleep</source>
            <year>1999</year>
            <month>Dec</month>
            <day>15</day>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1123</fpage>
            <page-range>1123-4</page-range>
            <pub-id pub-id-type="pmid">10617173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavel-Greant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lehmann-Horn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jurkat-Rott</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.</article-title>
            <source>Acta Myol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-33</page-range>
            <pub-id pub-id-type="pmid">23097604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klingler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lehmann-Horn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jurkat-Rott</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Complications of anaesthesia in neuromuscular disorders.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-206</page-range>
            <pub-id pub-id-type="pmid">15725581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23183.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackenzie</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yentis</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Anaesthetic management of labour and caesarean delivery of a patient with hyperkalaemic periodic paralysis.</article-title>
            <source>Int J Obstet Anesth</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-31</page-range>
            <pub-id pub-id-type="pmid">16774829</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
